The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly ophthalmology. Eye drops containing recombinant interferon stabilising the biological and physicochemical properties, stabilising resistance to microbial contamination, an antioxidant and a buffer mixture, contain antihistamine preparations specified in a group: antazoline, azelastin, tetryzoline, diphenhydramine hydrochloride as stabilising the biological and physicochemical properties, contains specified in th...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury.In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine bromphenirami...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury.In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine bromphenirami...

PURPOSE: To obtain the title activator capable of treating hardly curable infectious diseases such as periodontal diseases athlete's foot and opportunistic infection comprising a histamine H(sub 1) acceptor antagonist and/or a histamine H(sub 2) acceptor antagonist as active ingredients.CONSTITUTION: A polymorphonuclear leukocyte activator comprising histamine H(sub 1) acceptor antagonist such as diphenhydramine pyrilamine antazoline promethazine or chlorpheniramine and/or histamine H(sub 2) acc...

A method for lowering intraocular pressure in mammals by administering thereto an effective amount of antazoline i.e. 2-(N-benzylanilinomethyl)-2-imidazoline or its pharmacologically acceptable acid addition salts preferably antazoline phosphate.